DCDulce Helena Nunes Couto

Dulce Helena Nunes Couto

*This is an algorithmically generated author record based on publicly available information.

Dulce Helena Nunes Couto has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prognostic factors associated with survival in patients with colorectal cancer treated with capecitabine: A cohort study

    by Ariela Dutra Norberto de Oliveira, Patricia Kaiser Pedroso Cava, Vanessa Cristiane da Silva Ferreira, Camille Nigri Cursino, Jessica Pronestino de Lima Moreira, Thaísa Nogueira, Dulce Helena Nunes Couto, Sabrina Calil-Elias

    Introduction: Colorectal cancer is a major public health problem due to its high incidence and mortality rates worldwide. Various clinical and sociodemographic characteristics are intrinsically linked to this neoplasm and can have a significant influence on both survival estimates and the utilization of healthcare resources. Within this context, capecitabine has emerged as an oral antineoplastic agent used in the treatment of this type of cancer. Objective: The objective of this study was to evaluate the survival of patients diagnosed with colorectal cancer who initiated treatment with capecitabine. Method: This is a retrospective cohort study conducted at a cancer reference center in Rio de Janeiro, Brazil, based on data collected from medical records of patients treated between 2017 and 2019. Survival analysis was performed using the Kaplan-Meier method, and the Cox proportional hazards model was used to estimate hazard ratios (HRs). Results: For clinical progression-free survival (cPFS), the estimated event-free probability at 12 months was 72%, while for overall survival (OS) it was 83%. Staging and performance status were associated with a higher probability of death. For both cPFS and OS, stage IV disease was associated with an approximately 3-fold increase in risk, and poor performance status with an approximately 3-fold increase for cPFS and 4-fold for OS. Conclusion: The results obtained reinforce the importance of individualized assessments that consider clinical and functional parameters to define the most appropriate therapeutic strategy in patients selected for a capecitabine-containing regimen.


  • Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial

    by Patrícia Kaiser Pedroso Cava, Camille Nigri Cursino, Larissa Dos Santos Sebould Marinho, Ana Clara Duarte Dos Santos, Ariela Dutra Norberto De Oliveira, Larissa Rodrigues Nascimento, Vanessa Cristiane Da Silva Ferreira, Dulce Helena Nunes Couto, Jessica Pronestino De Lima Moreira, Thaísa Amorim Nogueira, et al.

    Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.

  • Open Access

    Custo-efetividade do pazopanibe comparado ao sunitinibe para câncer renal metastático na perspectiva de um hospital do Sistema Único de Saúde

    by Isandra Oliveira Meirelles, Dulce Helena Nunes Couto, Rodrigo Saar da Costa

    Resumo: O câncer renal é a 13ª neoplasia mais frequente no mundo. Entre 2012 e 2016, representou 1,48% das mortes por câncer no Brasil. A terapia de escolha para o tratamento de câncer renal metastático são os inibidores de tirosina quinase (ITK), sunitinibe e pazopanibe. Este artigo avalia o custo-efetividade do pazopanibe comparado ao sunitinibe no tratamento de câncer renal metastático. Foi realizada uma análise de custo-efetividade sob a perspectiva de um hospital federal do Sistema Único de Saúde. No modelo de árvore de decisão foram aplicados os desfechos de efetividade e segurança dos ITK. Os dados clínicos foram extraídos de prontuários e os custos diretos consultados em fontes oficiais do Ministério da Saúde. O custo de 10 meses de tratamento, englobando o valor dos ITK, procedimentos e manejo de eventos adversos, foi de R$ 98.677,19 para o pazopanibe e R$ 155.227,11 para o sunitinibe. Os medicamentos apresentaram efetividade estatisticamente equivalente e diferença estatisticamente significativa para o desfecho de segurança, no qual o pazopanibe obteve o melhor resultado. O pazopanibe, nesse contexto, é a tecnologia dominante quando os custos de tratamento são associados aos de manejo de eventos adversos.